Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines

Kenichi Takayasu, Shigeki Arii, Masatoshi Kudo, Takafumi Ichida, Osamu Matsui, Namiki Izumi, Yutaka Matsuyama, Michiie Sakamoto, Osamu Nakashima, Yonson Ku, Norihiro Kokudo, Masatoshi Makuuchi

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Background & Aims: Transcatheter arterial chemoembolization with lipiodol (TACE) is widely performed in patients with hepatocellular carcinoma (HCC) unsuitable for curative treatment. It has recently been recommended for patients with 2 or 3 tumors >3 cm or ≥4 tumors in a treatment algorithm proposed by Japanese guidelines. However, the best indication and appropriateness of the algorithm for TACE are still unclear. Methods: In 4966 HCC patients who underwent TACE, survival was evaluated based on tumor number, size and liver function; and the adequacy of the algorithm for TACE was validated. Exclusion criteria were: vascular invasion, extrahepatic metastasis, and prior treatment. The mean follow up period was 1.6 years. Results: The overall median and 5-year survivals were 3.3 years and 34%, respectively. Multivariate analysis revealed that Child-Pugh class, tumor number, size, alpha-fetoprotein, and des-gamma carboxy-prothrombin were independent predictors. The survival rate decreased as the tumor number (p = 0.0001) and size increased (p = 0.04 to p = 0.0001) in all but one subgroup in both Child-Pugh-A and -B. The stratification of these patients to four treatments in the algorithm showed potential ability to discriminate survivals of the resection and ablation (non-TACE) groups from those of the TACE group in Child-Pugh-B and partially in A. Conclusions: TACE showed higher survival rates in patients with fewer tumor numbers, smaller tumor size, and better liver function. The treatment algorithm proposed by the Japanese guidelines might be appropriate to discriminate the survival of patients with non-TACE from TACE therapy.

Original languageEnglish
Pages (from-to)886-892
Number of pages7
JournalJournal of Hepatology
Volume56
Issue number4
DOIs
Publication statusPublished - 2012 Apr

Fingerprint

Ethiodized Oil
Hepatocellular Carcinoma
Guidelines
Neoplasms
Therapeutics
Survival
Survival Rate
Liver
alpha-Fetoproteins
Blood Vessels
Multivariate Analysis
Neoplasm Metastasis

Keywords

  • Hepatocellular carcinoma (HCC)
  • Japanese guidelines
  • Prognostic factor
  • Transcatheter arterial chemoembolization (TACE)
  • Validation of treatment algorithm

ASJC Scopus subject areas

  • Hepatology

Cite this

Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. / Takayasu, Kenichi; Arii, Shigeki; Kudo, Masatoshi; Ichida, Takafumi; Matsui, Osamu; Izumi, Namiki; Matsuyama, Yutaka; Sakamoto, Michiie; Nakashima, Osamu; Ku, Yonson; Kokudo, Norihiro; Makuuchi, Masatoshi.

In: Journal of Hepatology, Vol. 56, No. 4, 04.2012, p. 886-892.

Research output: Contribution to journalArticle

Takayasu, K, Arii, S, Kudo, M, Ichida, T, Matsui, O, Izumi, N, Matsuyama, Y, Sakamoto, M, Nakashima, O, Ku, Y, Kokudo, N & Makuuchi, M 2012, 'Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines', Journal of Hepatology, vol. 56, no. 4, pp. 886-892. https://doi.org/10.1016/j.jhep.2011.10.021
Takayasu, Kenichi ; Arii, Shigeki ; Kudo, Masatoshi ; Ichida, Takafumi ; Matsui, Osamu ; Izumi, Namiki ; Matsuyama, Yutaka ; Sakamoto, Michiie ; Nakashima, Osamu ; Ku, Yonson ; Kokudo, Norihiro ; Makuuchi, Masatoshi. / Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. In: Journal of Hepatology. 2012 ; Vol. 56, No. 4. pp. 886-892.
@article{60310423070e4f81a1148696db2a2a36,
title = "Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines",
abstract = "Background & Aims: Transcatheter arterial chemoembolization with lipiodol (TACE) is widely performed in patients with hepatocellular carcinoma (HCC) unsuitable for curative treatment. It has recently been recommended for patients with 2 or 3 tumors >3 cm or ≥4 tumors in a treatment algorithm proposed by Japanese guidelines. However, the best indication and appropriateness of the algorithm for TACE are still unclear. Methods: In 4966 HCC patients who underwent TACE, survival was evaluated based on tumor number, size and liver function; and the adequacy of the algorithm for TACE was validated. Exclusion criteria were: vascular invasion, extrahepatic metastasis, and prior treatment. The mean follow up period was 1.6 years. Results: The overall median and 5-year survivals were 3.3 years and 34{\%}, respectively. Multivariate analysis revealed that Child-Pugh class, tumor number, size, alpha-fetoprotein, and des-gamma carboxy-prothrombin were independent predictors. The survival rate decreased as the tumor number (p = 0.0001) and size increased (p = 0.04 to p = 0.0001) in all but one subgroup in both Child-Pugh-A and -B. The stratification of these patients to four treatments in the algorithm showed potential ability to discriminate survivals of the resection and ablation (non-TACE) groups from those of the TACE group in Child-Pugh-B and partially in A. Conclusions: TACE showed higher survival rates in patients with fewer tumor numbers, smaller tumor size, and better liver function. The treatment algorithm proposed by the Japanese guidelines might be appropriate to discriminate the survival of patients with non-TACE from TACE therapy.",
keywords = "Hepatocellular carcinoma (HCC), Japanese guidelines, Prognostic factor, Transcatheter arterial chemoembolization (TACE), Validation of treatment algorithm",
author = "Kenichi Takayasu and Shigeki Arii and Masatoshi Kudo and Takafumi Ichida and Osamu Matsui and Namiki Izumi and Yutaka Matsuyama and Michiie Sakamoto and Osamu Nakashima and Yonson Ku and Norihiro Kokudo and Masatoshi Makuuchi",
year = "2012",
month = "4",
doi = "10.1016/j.jhep.2011.10.021",
language = "English",
volume = "56",
pages = "886--892",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines

AU - Takayasu, Kenichi

AU - Arii, Shigeki

AU - Kudo, Masatoshi

AU - Ichida, Takafumi

AU - Matsui, Osamu

AU - Izumi, Namiki

AU - Matsuyama, Yutaka

AU - Sakamoto, Michiie

AU - Nakashima, Osamu

AU - Ku, Yonson

AU - Kokudo, Norihiro

AU - Makuuchi, Masatoshi

PY - 2012/4

Y1 - 2012/4

N2 - Background & Aims: Transcatheter arterial chemoembolization with lipiodol (TACE) is widely performed in patients with hepatocellular carcinoma (HCC) unsuitable for curative treatment. It has recently been recommended for patients with 2 or 3 tumors >3 cm or ≥4 tumors in a treatment algorithm proposed by Japanese guidelines. However, the best indication and appropriateness of the algorithm for TACE are still unclear. Methods: In 4966 HCC patients who underwent TACE, survival was evaluated based on tumor number, size and liver function; and the adequacy of the algorithm for TACE was validated. Exclusion criteria were: vascular invasion, extrahepatic metastasis, and prior treatment. The mean follow up period was 1.6 years. Results: The overall median and 5-year survivals were 3.3 years and 34%, respectively. Multivariate analysis revealed that Child-Pugh class, tumor number, size, alpha-fetoprotein, and des-gamma carboxy-prothrombin were independent predictors. The survival rate decreased as the tumor number (p = 0.0001) and size increased (p = 0.04 to p = 0.0001) in all but one subgroup in both Child-Pugh-A and -B. The stratification of these patients to four treatments in the algorithm showed potential ability to discriminate survivals of the resection and ablation (non-TACE) groups from those of the TACE group in Child-Pugh-B and partially in A. Conclusions: TACE showed higher survival rates in patients with fewer tumor numbers, smaller tumor size, and better liver function. The treatment algorithm proposed by the Japanese guidelines might be appropriate to discriminate the survival of patients with non-TACE from TACE therapy.

AB - Background & Aims: Transcatheter arterial chemoembolization with lipiodol (TACE) is widely performed in patients with hepatocellular carcinoma (HCC) unsuitable for curative treatment. It has recently been recommended for patients with 2 or 3 tumors >3 cm or ≥4 tumors in a treatment algorithm proposed by Japanese guidelines. However, the best indication and appropriateness of the algorithm for TACE are still unclear. Methods: In 4966 HCC patients who underwent TACE, survival was evaluated based on tumor number, size and liver function; and the adequacy of the algorithm for TACE was validated. Exclusion criteria were: vascular invasion, extrahepatic metastasis, and prior treatment. The mean follow up period was 1.6 years. Results: The overall median and 5-year survivals were 3.3 years and 34%, respectively. Multivariate analysis revealed that Child-Pugh class, tumor number, size, alpha-fetoprotein, and des-gamma carboxy-prothrombin were independent predictors. The survival rate decreased as the tumor number (p = 0.0001) and size increased (p = 0.04 to p = 0.0001) in all but one subgroup in both Child-Pugh-A and -B. The stratification of these patients to four treatments in the algorithm showed potential ability to discriminate survivals of the resection and ablation (non-TACE) groups from those of the TACE group in Child-Pugh-B and partially in A. Conclusions: TACE showed higher survival rates in patients with fewer tumor numbers, smaller tumor size, and better liver function. The treatment algorithm proposed by the Japanese guidelines might be appropriate to discriminate the survival of patients with non-TACE from TACE therapy.

KW - Hepatocellular carcinoma (HCC)

KW - Japanese guidelines

KW - Prognostic factor

KW - Transcatheter arterial chemoembolization (TACE)

KW - Validation of treatment algorithm

UR - http://www.scopus.com/inward/record.url?scp=84858702846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858702846&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2011.10.021

DO - 10.1016/j.jhep.2011.10.021

M3 - Article

C2 - 22173160

AN - SCOPUS:84858702846

VL - 56

SP - 886

EP - 892

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 4

ER -